Skip to main content
letter
. 2013 Dec 22;16(3):466–467. doi: 10.1093/neuonc/not248

Fig. 1.

Fig. 1.

Left. BRAFV600E immunostaining in (a) human papillary thyroid cancer, positive control; (b) normal human brain, negative control; (c) one representative BRAFV600E-immunopositive MPNST; and (d) one representative BRAFV600E-immunonegative MPNST. Magnification, 200x; Scale bar, 50 microns. Right. summary of clinical, demographic, and survival data for individuals with MPNST.